Inmune Bio Inc's Comment on Sales, Marketing and Customers
The European Union regulatory framework for data and market exclusivity pertains to innovative medicinal products, specifically New Chemical Entities (NCEs). It establishes exclusivity periods that influence the market entry of generic, hybrid, or biosimilar products. The framework serves pharmaceutical companies developing innovative medicinal products, applicants for generic products, and holders of marketing authorizations (MAs) within the EU. Current proposals by the European Commission aim to reform pharmaceutical legislation, potentially affecting exclusivity periods and incentives for developing new antibiotics and orphan medicines.
INmune Bio, Inc., a Florida-based clinical-stage immunology corporation, has reported its conclusive agreements for a registered direct offering valued at $9.7 million. The offering is priced at-the-market under NASDAQ rules, based on the average of the past five days closing prices - $9.84 per share, also including $0.125 per warrant.Under the terms of the agreement, the company is undertaking the sale and purchase of 986,000 shares of its common stock. Concurrently, warrants to purchase up to 986,000 shares of common stock are part of the offering. The warrants are connected to INmune Bio’s ongoing Phase 2 Alzheimer s Disease program and come with an acceleration clause triggered by the revelation of pos...
Inmune Bio Inc’s Comment on Sales, Marketing and Customers
The European Union regulatory framework for data and market exclusivity pertains to innovative medicinal products, specifically New Chemical Entities (NCEs). It establishes exclusivity periods that influence the market entry of generic, hybrid, or biosimilar products. The framework serves pharmaceutical companies developing innovative medicinal products, applicants for generic products, and holders of marketing authorizations (MAs) within the EU. Current proposals by the European Commission aim to reform pharmaceutical legislation, potentially affecting exclusivity periods and incentives for developing new antibiotics and orphan medicines.
Sources:
Inmune Bio Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Inmune Bio Inc’s corporate clients.
For your research, we’ve provided 9 tables on Inmune Bio Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
